State Street Holds 5.2% Of Medtronic — Its Voting Power Covers Fewer Shares
The September 30 holding comes alongside progress for Medtronic's hypertension treatment and roughly $6.1 billion in annual free cash flow.
State Street reported a 5.2% stake in Medtronic, which makes medical devices and therapies, in a passive ownership disclosure filed Tuesday. The holding comprised 66,055,969 common shares, but State Street's shared voting authority covered 41,915,337 shares.
Ownership And Votes Differ
The position was measured on September 30, 2026. Tuesday was the reporting date, rather than the date of the underlying holding.
State Street reported shared disposal authority over 65,987,354 shares—the power to direct their sale. It had no sole voting or sole disposal authority. Beneficial ownership, voting authority and authority to sell therefore represent distinct measures of the position.
State Street certified that the securities were held as part of its regular business, rather than to seek control of Medtronic or influence who controls it.
Spyral Adds Clinical Evidence
Medtronic shares gained roughly 20% over the past month, as described in the original Tuesday report. Its market value was $131.5 billion as of 9:21 a.m. ET Tuesday.
The company's recent treatment news concerns Symplicity Spyral for hypertension. Medtronic reported that a post-approval study met its main goal, with blood-pressure reductions assessed at six months.
The FDA also expanded the device's labeling to include clinical evidence involving patients with isolated systolic hypertension, certain chronic kidney disease and type 2 diabetes.
Spyral sits within a broader medical-device business spanning pacemakers, heart valves, spinal and brain implants, surgical instruments and patient monitors. Medtronic reports Cardiovascular, Neuroscience and Medical Surgical segments and serves customers in more than 150 countries.
Medtronic generated around $6.1 billion in free cash flow over the latest twelve months.
Medtronic plans to report results on November 24, 2026. Management also plans to present growth targets at its December Investor Day.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: MEDTRONIC PLC (MDT) — SEC EDGAR
- Can Medtronic (MDT) Still Justify Its Price On Cash Flow? — Yahoo Finance
- Medtronic (MDT) Reports SPYRAL AFFIRM Results, Is It Still 9% Undervalued? — Yahoo Finance
- Is Blood Pressure Trial Success Altering The Investment Case For Medtronic (MDT)? — Yahoo Finance
- Medtronic (MDT) Wins FDA Label Expansion After Real World Symplicity Spyral Results — Yahoo Finance